Suppr超能文献

驱动蛋白的过表达介导乳腺癌细胞对多西他赛的耐药性。

Overexpression of kinesins mediates docetaxel resistance in breast cancer cells.

作者信息

De Sarmishtha, Cipriano Rocky, Jackson Mark W, Stark George R

机构信息

Department of Genetics and Pathology, Case Western Reserve University, Case Comprehensive Cancer Center, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.

出版信息

Cancer Res. 2009 Oct 15;69(20):8035-42. doi: 10.1158/0008-5472.CAN-09-1224. Epub 2009 Sep 29.

Abstract

Resistance to chemotherapy remains a major barrier to the successful treatment of cancer. To understand mechanisms underlying docetaxel resistance in breast cancer, we used an insertional mutagenesis strategy to identify proteins whose overexpression confers resistance. A strong promoter was inserted approximately randomly into the genomes of tumor-derived breast cancer cells, using a novel lentiviral vector. We isolated a docetaxel-resistant clone in which the level of the kinesin KIFC3 was elevated. When KIFC3 or the additional kinesins KIFC1, KIF1A, or KIF5A were overexpressed in the breast cancer cell lines MDA-MB231 and MDA-MB 468, the cells became more resistant to docetaxel. The binding of kinesins to microtubules opposes the stabilizing effect of docetaxel that prevents cytokinesis and leads to apoptosis. Our finding that kinesins can mediate docetaxel resistance might lead to novel therapeutic approaches in which kinesin inhibitors are paired with taxanes.

摘要

对化疗的耐药性仍然是癌症成功治疗的主要障碍。为了解乳腺癌中多西他赛耐药的潜在机制,我们采用插入诱变策略来鉴定那些过表达会导致耐药的蛋白质。使用一种新型慢病毒载体,将一个强启动子大致随机地插入源自肿瘤的乳腺癌细胞基因组中。我们分离出一个多西他赛耐药克隆,其中驱动蛋白KIFC3的水平升高。当在乳腺癌细胞系MDA-MB231和MDA-MB 468中过表达KIFC3或其他驱动蛋白KIFC1、KIF1A或KIF5A时,细胞对多西他赛的耐药性增强。驱动蛋白与微管的结合对抗了多西他赛阻止胞质分裂并导致细胞凋亡的稳定作用。我们发现驱动蛋白可介导多西他赛耐药性,这可能会带来新的治疗方法,即将驱动蛋白抑制剂与紫杉烷类药物联合使用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验